The Pharma Data

SEPTEMBER 30, 2021

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a replacement treatment that would keep metastatic cancers cornered from the lungs. It involves a bodily injection of a virus called the cowpea mosaic virus. The research was published Sept.

Virus 52

Virus Engineering Treatment Research 52

The Pharma Data

FEBRUARY 1, 2021

They spent about an hour at the Huanan Seafood Market, which was the site of an outbreak of the virus in December 2019, the Associated Press reported. Initially, experts suspected the new coronavirus came from wild animals sold at the market, but the site has been largely ruled out as a source of the virus. © 2021 HealthDay.

Vaccine 52

Vaccine Virus Compliance Marketing 52

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. Molecular insights of HIV Reverse transcriptase and it's inhibitors.

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company. population.

Virus 52

Virus Immune Response Vaccine Research 52

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. On April 15, 2021, I posted “ 3 Possible Origins of COVID: Lab Escapee, Evolution, or Mutator Genes?

Virus 52

Virus RNA DNA Science 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We Second Quarter 2021 Financial Results. Total second quarter 2021 revenue of $6.2 As of June 30, 2021, Gilead had $7.4

Science 52

Science Production Treatment FDA 52

The Pharma Data

JANUARY 27, 2021

27, 2021 — Heart disease remains the leading cause of death worldwide, with 18.6 million deaths attributed to cardiovascular disease (CVD) globally in 2019, according to a report from the American Heart Association published online Jan. © 2021 HealthDay. Posted: January 2021. WEDNESDAY, Jan. Virani, M.D.,

Disease 52

Disease Virus Pharmaceuticals 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. billion expected from signed advance purchase agreements for fiscal 2021, Bancel said in a Monday call with investors. 18, 2020 ). Martin Berman-Gorvine.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

Drug Discovery World

JULY 14, 2022

The same formulation of tecovirimat was approved by the US Food and Drug Administration (FDA) in 2018 and by Health Canada in late 2021 under the brand name TPOXX?for As we have learned in the ongoing COVID-19 pandemic, building robust stockpiles in response to infectious disease outbreaks is of vital importance worldwide.

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus.

Disease 69

Disease DNA Virus RNA 69

The Pharma Data

SEPTEMBER 30, 2021

We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”. In the U.S., About MenQuadfi In the U.S.,

Vaccine 52

Vaccine Research Virus Hospitals 52

The Pharma Data

JANUARY 11, 2021

Pfizer and BioNTech reported that their COVID-19 vaccine appears to be effective against a key mutation in new variants of the SARS-CoV-2 virus that causes COVID-19. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. A study published by the U.S. Other Industry News. and now 501.V2,

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

Drug Discovery World

JUNE 7, 2023

Under the leadership of CEO and Founder, Professor Helen McCarthy, pHion has made significant progress since invoX’s initial investment in June 2021, with advances made across all pre-clinical programs and the establishment of a laboratory in Belfast, Northern Ireland for the production of pHion’s mRNA vaccines.

Vaccine 130

Vaccine Testimonials Clinical Trials Laboratories 130

The Pharma Data

JULY 23, 2021

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print , demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta/Gamma variants of the SARS-CoV-2 virus.

Disease 52

Disease Virus Vaccine Trials 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — OyaGen, Inc. A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ ’ (2021) Viruses 13:52 [link]. ROCHESTER, N.Y. , Bennett et al., About OYA1. OYA1 (a.k.a. HHSN272201800013C (S.Y.,

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

AUGUST 3, 2021

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. More than 60 million patients worldwide suffer from this disease, approx.

Research 52

Research Clinical Trials Treatment Production 52

The Pharma Data

DECEMBER 21, 2020

Kaiser Permanente has announced that it will extend its waiver for most member out-of-pocket costs for inpatient and outpatient services related to the treatment of COVID-19 through at least March 31, 2021 , or as long as the ongoing public health emergency lasts. OAKLAND, Calif. ,

Virus 52

Virus Clinical Research Regulations Treatment 52

The Pharma Data

JANUARY 21, 2021

21, 2021 — U.S. President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. © 2021 HealthDay. Posted: January 2021. THURSDAY, Jan. Source link.

Vaccine 52

Vaccine Virus RNA Research 52

The Pharma Data

JANUARY 15, 2021

16, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Virus 52

Virus Laboratories Hospitals Vaccine 52

Drug Discovery World

OCTOBER 31, 2022

The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems. . 5 predominance for immunocompromised adults. .

Vaccine 130

Vaccine Virus Hospitals Treatment 130

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. Alzheimer’s disease), or by initiating a new one. There is strong evidence for widespread brain changes following Covid-19. depression).

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

JANUARY 22, 2021

23, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Virus 40

Virus Vaccine Hospitals Laboratories 40

The Pharma Data

JANUARY 16, 2021

17, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians, public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Hospitals 52

Hospitals Vaccine Laboratories Virus 52

Drug Discovery World

MAY 22, 2023

from 2021 and 54.8% In 2022, the most valuable RNA platform partnership saw CSL-Sequirus pay Arcturus $200 million up front and offer more than $4 billion in potential development and commercial milestones for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines. A total of $60.8

Pharma Companies 130

Pharma Companies RNA Therapies Virus 130

Drug Discovery World

JULY 3, 2023

from 2021 and 54.8% Another recent start-up, UK-based Scarlet Therapeutics, is developing a platform that makes modified therapeutic red blood cells to potentially treat a wide range of diseases. High interest rates and other economic challenges, along with low investment, have made it very difficult for companies to raise funding.

Science 130

Science Pharma Companies Marketing Virus 130

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Adeno-associated virus vector as a platform for gene therapy delivery.

Engineering 104

Engineering Virus Therapies Immune Response 104

Drug Target Review

JULY 19, 2023

Most vaccines cannot be self-administered, so distribution requires access to trained healthcare services – a big problem in developing countries, which is where infectious disease burdens are highest. A leading company in this field, Seattle’s Lumen Bioscience, is best known for its orally delivered antibodies targeting diseases such as C.

Vaccine 96

Vaccine Engineering Disease Virus 96

EG Life Sciences

FEBRUARY 15, 2023

To perform this, CDER is required to understand the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat. Approval processes were slow in comparison to 2020 and 2021, where 53 and 50 approvals were achieved respectively.

Drug Development 52

Drug Development FDA Approval Virus Drugs 52

The Pharma Data

SEPTEMBER 8, 2021

Roche to acquire the TIB Molbiol Group with the expectation to close in fourth quarter of 2021. TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The majority of assays are used to test for infectious diseases.

Virus 52

Virus Assay Development Disease Research 52

The Pharma Data

JANUARY 26, 2021

26, 2021 — The first known U.S. “We know that even as we work hard to defeat COVID-19, the virus continues to evolve as all viruses do,” Minnesota Health Commissioner Jan Malcolm said in a statement. Centers for Disease Control and Prevention. © 2021 HealthDay. Posted: January 2021. Professional.

Virus 52

Virus Disease Research 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — The bacteria in your gut may play a role in the severity of COVID-19 infection and the strength of your immune system response, a new study suggests. “Restoration of the missing beneficial bacteria might boost our immunity against SARS-CoV2 virus and hasten recovery from the disease,” she said.

Virus 52

Virus Hospitals Disease Research 52

The Pharma Data

SEPTEMBER 5, 2021

Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022. Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. Neither of the two vaccines approved in the United States — made by Pfizer-BioNTech and Moderna — contains the live virus.

Vaccine 52

Vaccine Virus DNA Doctors 52

PerkinElmer

JUNE 14, 2021

Meanwhile, researchers are continuing to investigate possible treatments for patients suffering with the disease. In October last year, remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. Sci Rep 11, 5890 (2021). Cell growth was determined using a PerkinElmer EnSight ® multimode plate reader.

Virus 52

Virus RNA Vaccine Treatment 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

AUGUST 9, 2021

The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus. This should prevent both clinical disease and virus transmission, to halt the spread of the COVID-19 pandemic.

Vaccine 52

Vaccine Virus Immune Response Disease 52